Two candidate respiratory syncytial virus (RSV) vaccines generated positive data in Phase 1/2 studies, paving the way for the start of Phase 3 trials in the coming months, GlaxoSmithKline Plc announced on 21 October. The first vaccine has been developed for healthy women of child-bearing age, and the second for older adults. A third vaccine for infants is also in development, with data expected to be reported at the European Society for Paediatric Infectious Diseases meeting on 26 to 29 October.
